Clostridium difficile infection in patients with inflammatory bowel disease

Clostridium difficile is a bacterium widely distributed in the human environment. In the last decade the incidence and severity of Clostridium difficile infection has grown, particularly in Europe and North America, making it one of the more common nosocomial infections. A group particularly susceptible to Clostridium difficile infection are patients with inflammatory bowel disease, especially those with involvement of the colon. This paper presents relevant data on Clostridium difficile infections in inflammatory bowel disease patients, including epidemiology, pathogenesis, diagnosis and treatment.

[1]  T. Wong,et al.  INTRA-ABDOMINAL INFECTIONS , HEPATITIS , AND GASTROENTERITIS ( T STEINER , 2016 .

[2]  L. Brandt,et al.  Clostridium difficile Infection and Inflammatory Bowel Disease , 2013, Journal of clinical gastroenterology.

[3]  A. Radzikowski,et al.  Clostridium difficile infection in newly diagnosed pediatric patients with inflammatory bowel disease: Prevalence and risk factors , 2012, Inflammatory bowel diseases.

[4]  D. Crook,et al.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. , 2012, The Lancet. Infectious diseases.

[5]  T. Barrett,et al.  Clostridium difficile Infection and Inflammatory Bowel Disease: A Review , 2011, Gastroenterology research and practice.

[6]  D. Gerding,et al.  Clostridium difficile infection in 2010: Advances in pathogenesis, diagnosis and management of CDI , 2011, Nature Reviews Gastroenterology &Hepatology.

[7]  J. Bartlett.  Detection of Clostridium difficile Infection , 2010, Infection Control & Hospital Epidemiology.

[8]  U. Navaneethan,et al.  Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. , 2010, World journal of gastroenterology.

[9]  A. Ananthakrishnan,et al.  Impact of Clostridium difficile on inflammatory bowel disease , 2010, Expert review of gastroenterology & hepatology.

[10]  A. Simor.  Diagnosis, Management, and Prevention of Clostridium difficile Infection in Long‐Term Care Facilities: A Review , 2010, Journal of the American Geriatrics Society.

[11]  J. Maul,et al.  Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. , 2010, Journal of Crohn's & colitis.

[12]  C. Vaishnavi.  Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. , 2010, The Indian journal of medical research.

[13]  D. Gerding,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) , 2010, Infection Control & Hospital Epidemiology.

[14]  J. Maul,et al.  Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  S. Schneeweiss,et al.  Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections , 2009, Alimentary pharmacology & therapeutics.

[16]  Mark H. Wilcox,et al.  Clostridium difficile infection: new developments in epidemiology and pathogenesis , 2009, Nature Reviews Microbiology.

[17]  R. P. Ross,et al.  The Vexed Relationship Between Clostridium Difficile and Inflammatory Bowel Disease: An Assessment of Carriage in an Outpatient Setting Among Patients in Remission , 2009, The American Journal of Gastroenterology.

[18]  T. Concannon,et al.  Epidemiology of Clostridium difficile Colitis in Hospitalized Patients with Inflammatory Bowel Diseases , 2009, Diseases of the colon and rectum.

[19]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[20]  N. Powell,et al.  Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent? , 2008, Gut.

[21]  G. Kaplan,et al.  A National Survey of the Prevalence and Impact of Clostridium difficile Infection Among Hospitalized Inflammatory Bowel Disease Patients , 2008, The American Journal of Gastroenterology.

[22]  A. Ananthakrishnan,et al.  Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease , 2007, Gut.

[23]  Kimberly A. Reske,et al.  Incidence of Clostridium difficile infection in inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  Dawn B. Beaulieu,et al.  Impact of Clostridium difficile on inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  R. Nelson,et al.  Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. , 2007, The Cochrane database of systematic reviews.

[26]  D. Musher,et al.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Lynne V McFarland,et al.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.

[28]  R. Guerrant,et al.  Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis , 1997, Clinical and diagnostic laboratory immunology.

[29]  R. Guerrant,et al.  Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes , 1997, Infection and immunity.

[30]  R. Pounder,et al.  Clostridium difficile and inflammatory bowel disease. , 1983, Gut.

[31]  Y. Trnka,et al.  THERAPEUTIC IMPLICATIONS OF CLOSTRIDIUM DIFFICILE TOXIN DURING RELAPSE OF CHRONIC INFLAMMATORY BOWEL DISEASE , 1980, The Lancet.

[32]  R. Barton,et al.  Clindamycin-associated colitis. A prospective study. , 1974, Annals of internal medicine.

[33]  I. C. Hall,et al.  INTESTINAL FLORA IN NEW-BORN INFANTS: WITH A DESCRIPTION OF A NEW PATHOGENIC ANAEROBE, BACILLUS DIFFICILIS , 1935 .